cannabis indica

Palmitoiletanolamida (PEA)

termo de indexação original: Palmitoylethanolamide (PEA)

O que é Palmitoiletanolamida (PEA)

A palmitoiletanolamida, ou PEA, é uma N-aciletanolamida produzida pelo próprio corpo — da mesma família química da anandamida, mas derivada do ácido palmítico em vez do araquidônico. Também está presente em alimentos como gema de ovo, amendoim e soja.

Apesar do parentesco, a PEA não ativa diretamente os receptores CB1 e CB2. Age principalmente pelo receptor nuclear PPAR-α e, indiretamente, prolonga a ação da anandamida ao competir pelas mesmas enzimas de degradação — um mecanismo descrito como efeito entourage.

Foi identificada nos anos 1950 e ganhou atenção por meio da pesquisa de Rita Levi-Montalcini, que na década de 1990 descreveu seu papel na modulação de mastócitos. É estudada sobretudo em contextos de dor e inflamação, e aparece neste acervo com frequência considerável para um composto que não é um canabinoide no sentido estrito.

No acervo

O acervo do Cannabis Indica reúne 224 estudos científicos que tocam o composto Palmitoiletanolamida (PEA), publicados entre 2001 e 2024. Pela leitura automatizada, 206 (92%) foram classificados como favoráveis, 10 (4%) como inconclusivos e 8 (4%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (70 estudos), seguido de estudo em animais (56). As condições mais associadas são Inflamação, Dor e Dor — Crônica.

Estudos indexados
224
Período coberto
2001–2024
Favoráveis
206 · 92%
Inconclusivos
10 · 4%
Desfavoráveis
8 · 4%
Termo original
Palmitoylethanolamide (PEA)

O acervo em números

Tipo de estudo

Metanálise70
Estudo em Animais56
Ensaio Clínico48
Ensaio Clínico Duplo-Cego30
Estudo Laboratorial16
Metanálise Clínica4

Direção do resultado

Favorável206
Inconclusivo10
Desfavorável8

Por década

2000s6
2010s99
2020s119

224 estudos

Filtrar e buscar no acervo →
  1. 2024

    Acute and Long-Term Effects of App-Delivered Heartfulness Meditation on Psychological Outcomes and the Endocannabinoid Signaling System in Cyclic Vomiting Syndrome

  2. 2024

    Design of Mixed Medicinal Plants, Rich in Polyphenols, Vitamins B, and Palmitoylethanolamide-Based Supplement to Help Reduce Nerve Pain: A Preclinical Study

    FavorávelEstudo LaboratorialDorInflamaçãoEstresse Oxidativo+4
  3. 2024

    Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants-A Double-Blind Randomised Controlled Study

    FavorávelEnsaio ClínicoDorDor — CrônicaEnxaqueca
  4. 2024

    Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis

    FavorávelMetanálise ClínicaDorDor — Crônica
  5. 2024

    Palmitoylethanolamide and Luteolin for postinfectious olfactory disorders: How clinically meaningful is its effect?

    FavorávelEnsaio ClínicoCOVID-19EstresseSíndrome do Desconforto Respiratório Agudo+1
  6. 2024

    Palmitoylethanolamide and polydatin in pediatric irritable bowel syndrome: A multicentric randomized controlled trial

    FavorávelEnsaio Clínico Duplo-CegoDorSíndrome do Intestino Irritável
  7. 2024

    The Effect of Palmitoylethanolamide (PEA) on Skeletal Muscle Hypertrophy, Strength, and Power in Response to Resistance Training in Healthy Active Adults: A Double-Blind Randomized Control Trial

    FavorávelEnsaio Clínico Duplo-CegoDorInsônia e Distúrbios do SonoQualidade de Vida
  8. 2023

    Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABAB-ergic activity and cortical plasticity in long COVID-19 syndrome

    FavorávelEnsaio Clínico Duplo-CegoInflamaçãoDisfunção CognitivaEstresse Oxidativo2-Araquidonoilglicerol (2-AG)+1
  9. 2023

    Effect of any form of steroids in comparison with that of other medications on the duration of olfactory dysfunction in patients with COVID-19: A systematic review of randomized trials and quasi-experimental studies

    FavorávelMetanáliseInflamaçãoDepressãoCOVID-19
  10. 2023

    Endocannabinoid 2-Arachidonoylglycerol Synthesis and Metabolism at Neuronal Nuclear Matrix Fractions Derived from Adult Rat Brain Cortex

    FavorávelEstudo LaboratorialEstresse OxidativoAnandamida (AEA)Endocanabinoide (não especificado)+2
  11. 2023

    In Vitro and In Vivo Safety of Hyaluronic Acid-Decorated Microparticles for Intravitreal Injection of Palmitoylethanolamide, Citicoline, or Glial-Cell-Derived Neurotrophic Factor

    FavorávelEstudo LaboratorialDorInflamaçãoGlaucoma+1
  12. 2023

    Palmitoylethanolamide counteracts high-fat diet-induced gut dysfunction by reprogramming microbiota composition and affecting tryptophan metabolism

    FavorávelEstudo em AnimaisInflamaçãoDoenças Cardiovasculares (DCV)ObesidadeMicrobiomaDieta+4
  13. 2023

    Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials

    FavorávelMetanálise ClínicaDorInflamaçãoDor — CrônicaAnandamida (AEA)+3
  14. 2023

    Parosmia COVID-19 Related Treated by a Combination of Olfactory Training and Ultramicronized PEA-LUT: A Prospective Randomized Controlled Trial

    FavorávelEnsaio ClínicoDorInflamaçãoDor — Neuropatia Periférica+1
  15. 2023

    Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence

  16. 2023

    Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer's disease: A systematic review and meta-analysis of animal studies

  17. 2023

    Systemic Changes in Endocannabinoids and Endocannabinoid-like Molecules in Response to Partial Nephrectomy-Induced Ischemia in Humans

  18. 2023

    The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis-A Double-Blind Placebo-Controlled Trial

    FavorávelEnsaio Clínico Duplo-CegoInflamaçãoDermatite de Contato Alérgica
  19. 2023

    The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection-A Double Blind, Randomised, Placebo-Controlled Trial

    FavorávelEnsaio Clínico Duplo-CegoInfecções BacterianasEstresseSíndrome do Desconforto Respiratório Agudo+2
  20. 2023

    Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial

    FavorávelEnsaio Clínico Duplo-CegoDoenças NeurodegenerativasCOVID-19
  21. 2022

    (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders

  22. 2022

    A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoAnsiedadeAnandamida (AEA)+6
  23. 2022

    Acute and long-term exercise differently modulate plasma levels of oxylipins, endocannabinoids, and their analogues in young sedentary adults: A sub-study and secondary analyses from the ACTIBATE randomized controlled-trial

  24. 2022

    Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial

    FavorávelEnsaio Clínico Duplo-CegoDepressãoDisfunção CognitivaPsicoseAnandamida (AEA)+4
  25. 2022

    Alterations of the endocannabinoid system and circulating and peripheral tissue levels of endocannabinoids in sarcopenic rats

  26. 2022

    Biomarkers and treatments for mood disorders encompassing the neurosteroid and endocannabinoid systems

  27. 2022

    Cannabinoid therapeutics in orofacial pain management: a systematic review

  28. 2022

    Cannabinoids as anticancer drugs: current status of preclinical research

  29. 2022

    Cannabinoids as Glial Cell Modulators in Ischemic Stroke: Implications for Neuroprotection

  30. 2022

    Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review

    FavorávelMetanáliseDorCâncerInflamaçãoAnandamida (AEA)Tetraidrocanabinol (THC)+28
  31. 2022

    Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications

    FavorávelMetanáliseDorInflamaçãoAnsiedadeAnandamida (AEA)+17
  32. 2022

    Cutaneous Squamous Cell Carcinoma and Lichen Simplex Chronicus Successfully Treated with Topical Cannabinoid Oil: A Case Report and Summary of Cannabinoids in Dermatology

  33. 2022

    Design, Characterization, and In Vitro Assays on Muscle Cells of Endocannabinoid-like Molecule Loaded Lipid Nanoparticles for a Therapeutic Anti-Inflammatory Approach to Sarcopenia

    FavorávelEstudo LaboratorialCondições GeriátricasSarcopenia
  34. 2022

    Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study

  35. 2022

    Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes

    FavorávelEstudo LaboratorialDoenças de PeleAnandamida (AEA)Endocanabinoide (não especificado)+7
  36. 2022

    Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption

  37. 2022

    Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

  38. 2022

    Exploring the endocannabinoidome in genetically obese (ob/ob) and diabetic (db/db) mice: Links with inflammation and gut microbiota

  39. 2022

    Expression and Functions of the CB 2 Receptor in Human Leukocytes

  40. 2022

    FABP5 deletion in nociceptors augments endocannabinoid signaling and suppresses TRPV1 sensitization and inflammatory pain

    FavorávelEstudo em AnimaisDorAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  41. 2022

    Herbal Cannabis Use Is Not Associated with Changes in Levels of Endocannabinoids and Metabolic Profile Alterations among Older Adults

  42. 2022

    Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

  43. 2022

    In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils

    FavorávelEstudo LaboratorialDorCâncerInflamaçãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+14
  44. 2022

    Influence of diet on acute endocannabinoidome mediator levels post exercise in active women, a crossover randomized study

  45. 2022

    Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain

    FavorávelMetanáliseEnxaquecaAnandamida (AEA)Endocanabinoide (não especificado)+4
  46. 2022

    Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies

  47. 2022

    Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies

    DesfavorávelMetanáliseDorCâncerInflamaçãoAnandamida (AEA)THC Farmacêutico+14
  48. 2022

    Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules

    InconclusivoEstudo em AnimaisDorCanabinol (CBN)Ácido Tetraidrocanabinólico (THC-a)
  49. 2022

    Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional Viewpoint

  50. 2022

    Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice

    FavorávelEstudo em AnimaisInflamaçãoAnsiedadeDoenças Neurodegenerativas+3
  51. 2022

    Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial

    FavorávelEnsaio Clínico Duplo-CegoCâncerInflamaçãoDoenças Cardiovasculares (DCV)2-Araquidonoilglicerol (2-AG)+6
  52. 2022

    Palmitoylethanolamide-based nutraceutical Calmux® in preventive treatment of migraine

    FavorávelEnsaio ClínicoDorInflamaçãoEnxaqueca
  53. 2022

    Role of the endocannabinoid system in the pathophysiology of endometriosis and therapeutic implications

  54. 2022

    Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations

  55. 2022

    Sex differences in endocannabinoids during 3 years of Mediterranean diet intervention: Association with insulin resistance and weight loss in a population with metabolic syndrome

  56. 2022

    Targeting the Endocannabinoidome in Pancreatic Cancer

  57. 2022

    The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDor — AgudaAnandamida (AEA)
  58. 2022

    The Endocannabinoid System and Physical Activity—A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders

  59. 2022

    Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence

    FavorávelMetanálise ClínicaDorInflamaçãoDisfunção Cognitiva+9
  60. 2022

    Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial

    FavorávelEnsaio Clínico Duplo-CegoInflamaçãoCOVID-19
  61. 2022

    Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?

  62. 2021

    Anti-inflammatory activity of palmitoylethanolamide ameliorates osteoarthritis induced by monosodium iodoacetate in Sprague–Dawley rats

    FavorávelEstudo em AnimaisInflamaçãoEstresse OxidativoArtrite+1
  63. 2021

    Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide?

    FavorávelMetanáliseAplicações Veterinárias
  64. 2021

    Circulating fatty acids and endocannabinoidome-related mediator profiles associated to human longevity

    FavorávelMetanáliseLongevidadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  65. 2021

    Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase

  66. 2021

    Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain

    FavorávelEstudo em AnimaisDorInflamaçãoDor — CrônicaEndocanabinoide (não especificado)+3
  67. 2021

    Efficacy of a fixed combination of palmitoylethanolamide and acetyl-l-carnitine (PEA+ALC FC) in the treatment of neuropathies secondary to rheumatic diseases

    FavorávelEnsaio ClínicoDorInflamaçãoDor — Crônica+4
  68. 2021

    Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia/amotivation in a general population cohort

    FavorávelMetanáliseDepressãoPsicoseDesequilíbrio do MicrobiomaMicrobioma
  69. 2021

    Endocannabinoids and Heart Rate Variability Alterations after Exposure to Prolonged Intensive Physical Exercise of the Hellenic Navy SEALs

    FavorávelEnsaio ClínicoEstresse OxidativoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  70. 2021

    Engineered Lactobacillus paracasei Producing Palmitoylethanolamide (PEA) Prevents Colitis in Mice

  71. 2021

    GPR119 and GPR55 as Receptors for Fatty Acid Ethanolamides, Oleoylethanolamide and Palmitoylethanolamide

    FavorávelMetanáliseDorInflamaçãoDor — Crônica+3
  72. 2021

    Gut barrier and microbiota changes with glycine and branched-chain amino acid supplementation in chronic haemodialysis patients

    DesfavorávelEnsaio Clínico Duplo-CegoInflamaçãoInsuficiência RenalAnandamida (AEA)Endocanabinoide (não especificado)+3
  73. 2021

    In vivo brain levels of acetylcholine and 5-hydroxytryptamine after oleoylethanolamide or palmitoylethanolamide administrations are mediated by PPARα engagement

    FavorávelEstudo em AnimaisInsônia e Distúrbios do SonoVirodamina (O-AEA)
  74. 2021

    Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models

  75. 2021

    Management of Acute Lung Injury: Palmitoylethanolamide as a New Approach

    FavorávelEstudo em AnimaisInflamaçãoCOVID-19Estresse+1
  76. 2021

    Micro Composite Palmitoylethanolamide/Rutin Reduces Vascular Injury through Modulation of the Nrf2/HO-1 and NF-kB Pathways

    FavorávelEstudo LaboratorialInflamaçãoDoenças Cardiovasculares (DCV)Estresse Oxidativo+1
  77. 2021

    Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation

    FavorávelMetanáliseInflamaçãoCOVID-19
  78. 2021

    Palmitoylethanolamide (PEA) in the treatment of neuropathic pain: a case study

    FavorávelMetanáliseDorDor — Neuropatia PeriféricaHerpes+1
  79. 2021

    Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence

  80. 2021

    Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study

    FavorávelEnsaio Clínico Duplo-CegoInsônia e Distúrbios do Sono
  81. 2021

    Palmitoylethanolamide Modulation of Microglia Activation: Characterization of Mechanisms of Action and Implication for Its Neuroprotective Effects

    FavorávelEstudo LaboratorialInflamação
  82. 2021

    Palmitoylethanolamide: A Natural Compound for Health Management

    FavorávelMetanáliseDorInflamaçãoDor — Crônica+1
  83. 2021

    Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition

  84. 2021

    Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results

    FavorávelEnsaio ClínicoCOVID-19
  85. 2021

    Synthetic Cannabinoids and Cathinones Cardiotoxicity: Facts and Perspectives

  86. 2021

    Systematic review of the impact of cannabinoids on neurobehavioral outcomes in preclinical models of traumatic and nontraumatic spinal cord injury

  87. 2021

    The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis

  88. 2021

    The Current and Potential Application of Medicinal Cannabis Products in Dentistry

  89. 2021

    The Nutraceutical N-Palmitoylethanolamide (PEA) Reveals Widespread Molecular Effects Unmasking New Therapeutic Targets in Murine Varicocele

    FavorávelEstudo em AnimaisInfertilidade Masculina
  90. 2021

    Ultramicronized Palmitoylethanolamide in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation

    FavorávelEstudo em AnimaisInflamaçãoCOVID-19Sepse
  91. 2020

    ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain

    FavorávelMetanáliseDorDor — Neuropatia Periférica
  92. 2020

    Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain

  93. 2020

    Associating Emergency Medical Services personnel's workload, trauma exposure, and health with the cortisol, endocannabinoid, and N-acylethanolamine concentrations in their hair

    DesfavorávelEnsaio ClínicoDorAnsiedadeDepressãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  94. 2020

    Astrocytic palmitoylethanolamide pre-exposure exerts neuroprotective effects in astrocyte-neuron co-cultures from a triple transgenic mouse model of Alzheimer's disease

    FavorávelEstudo LaboratorialInflamaçãoEstresse OxidativoDoenças Neurodegenerativas+1
  95. 2020

    Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome

  96. 2020

    Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat

  97. 2020

    Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram

    FavorávelEnsaio Clínico Duplo-CegoGlaucomaQualidade de Vida
  98. 2020

    Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions, High Frequency Oscillations, and GABAergic Transmission in Patients with Frontotemporal Dementia

    FavorávelEnsaio ClínicoDemência
  99. 2020

    First evidence on the role of palmitoylethanolamide in energy homeostasis in fish

    FavorávelEstudo em AnimaisSíndrome MetabólicaAnorexia (perda de apetite)
  100. 2020

    Food supplements based on palmitoylethanolamide plus hydroxytyrosol from olive tree or Bacopa monnieri extracts for neurological diseases

  101. 2020

    Impact of a weight loss and fitness intervention on exercise-associated plasma oxylipin patterns in obese, insulin-resistant, sedentary women

  102. 2020

    Impaired Duodenal Palmitoylethanolamide Release Underlies Acid-Induced Mast Cell Activation in Functional Dyspepsia

  103. 2020

    Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment

    FavorávelMetanáliseSíndrome do Intestino Irritável
  104. 2020

    Measuring the placebo effect in carpal tunnel syndrome

    FavorávelEnsaio Clínico Duplo-CegoDorDor — CrônicaDor — Neuropatia Periférica+2
  105. 2020

    N-Acylphosphatidylethanolamines and N-acylethanolamines increase in saliva upon food mastication: the influence of the individual nutritional status and fat type in food

    FavorávelEnsaio ClínicoObesidadeAnandamida (AEA)Endocanabinoide (não especificado)+1
  106. 2020

    Palmitoylethanolamide (PEA) reduces postoperative adhesions after experimental strabismus surgery in rabbits by suppressing canonical and non-canonical TGFβ signaling through PPARα

    FavorávelEstudo em AnimaisDorDor — Ocular
  107. 2020

    Palmitoylethanolamide counteracts brain fog improving depressive-like behaviour in obese mice: Possible role of synaptic plasticity and neurogenesis

    FavorávelEstudo em AnimaisDepressãoObesidadeSíndrome Metabólica
  108. 2020

    Palmitoylethanolamide counteracts hepatic metabolic inflexibility modulating mitochondrial function and efficiency in diet-induced obese mice

    FavorávelEstudo em AnimaisEstresse OxidativoDiabetesSíndrome Metabólica+2
  109. 2020

    Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries—A Systematic Review

    FavorávelMetanáliseInflamaçãoDoenças NeurodegenerativasEsclerose Múltipla+4
  110. 2020

    Potential Mechanisms Involved in Palmitoylethanolamide-Induced Vasodepressor Effects in Rats

  111. 2020

    PPARα-Dependent Effects of Palmitoylethanolamide Against Retinal Neovascularization and Fibrosis

    FavorávelEstudo em AnimaisInflamaçãoDoenças da RetinaDegeneração Macular
  112. 2020

    Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies

  113. 2020

    The Basal Pharmacology of Palmitoylethanolamide

    FavorávelMetanáliseDorInflamaçãoDor — Crônica
  114. 2020

    The Effect of Orally Dosed Levagen+™ (palmitoylethanolamide) on Exercise Recovery in Healthy Males—A Double-Blind, Randomized, Placebo-Controlled Study

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDor — Aguda
  115. 2020

    The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study

  116. 2020

    The Endocannabinoid System May Modulate Sleep Disorders in Aging

  117. 2020

    The Protective Effects of Pre- and Post-Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats

    FavorávelEstudo em AnimaisDorInflamaçãoDor — Aguda
  118. 2020

    Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study

    FavorávelEnsaio ClínicoEnxaqueca
  119. 2020

    Ultramicronized Palmitoylethanolamide and Paracetamol, a New Association to Relieve Hyperalgesia and Pain in a Sciatic Nerve Injury Model in Rat

    FavorávelEstudo em AnimaisDorInflamaçãoEstresse Oxidativo+3
  120. 2019

    A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis

    FavorávelEstudo em AnimaisEsclerose MúltiplaEncefalite e MieliteImunodeficiência por Trauma
  121. 2019

    A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeDepressãoInsônia e Distúrbios do Sono
  122. 2019

    Co-ultraPEALut: Role in Preclinical and Clinical Delirium Manifestations

    FavorávelEnsaio ClínicoInflamaçãoDisfunção CognitivaEstresse Oxidativo
  123. 2019

    Effect of dietary supplementation with ultramicronized palmitoylethanolamide in maintaining remission in cats with nonflea hypersensitivity dermatitis: a double-blind, multicentre, randomized, placebo-controlled study

    FavorávelEstudo em AnimaisAplicações VeterináriasDermatite de Contato AlérgicaPrurido
  124. 2019

    Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer

  125. 2019

    Micronized Palmitoylethanolamide-Polydatin Reduces the Painful Symptomatology in Patients with Interstitial Cystitis/Bladder Pain Syndrome

    FavorávelEnsaio ClínicoDorInflamaçãoDor — Crônica+3
  126. 2019

    Micronized Palmitoylethanolamide: A Post Hoc Analysis of a Controlled Study in Patients with Low Back Pain – Sciatica

    FavorávelMetanáliseDorInflamaçãoDor — Crônica+1
  127. 2019

    N-Palmitoylethanolamide Exerts Antidepressant-Like Effects in Rats: Involvement of PPAR α Pathway in the Hippocampus

    FavorávelEstudo em AnimaisDepressão
  128. 2019

    N-Palmitoylethanolamide-Oxazoline Protects against Middle Cerebral Artery Occlusion Injury in Diabetic Rats by Regulating the SIRT1 Pathway

    FavorávelEstudo em AnimaisInflamaçãoEstresse OxidativoDiabetes+1
  129. 2019

    Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial

    FavorávelEnsaio Clínico Duplo-CegoInflamaçãoDII — Doença Inflamatória Intestinal
  130. 2019

    Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity

  131. 2019

    Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of Treatment

    FavorávelEnsaio ClínicoMiastenia Gravis
  132. 2019

    The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review

    FavorávelMetanáliseDorDepressãoDoença de Parkinson+5
  133. 2019

    Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets

  134. 2019

    Ultramicronized Palmitoylethanolamide (um-PEA) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients

    FavorávelMetanáliseDorDor — CrônicaFibromialgia
  135. 2018

    Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy

    FavorávelEstudo em AnimaisEpilepsiaOutros Compostos Relacionados
  136. 2018

    Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial

    FavorávelEnsaio Clínico Duplo-CegoAnsiedadeDisfunção CognitivaPsicoseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  137. 2018

    Effects of a Weight Loss Program on Metabolic Syndrome, Eating Disorders and Psychological Outcomes: Mediation by Endocannabinoids?

  138. 2018

    Impaired anandamide/palmitoylethanolamide signaling in hippocampal glutamatergic neurons alters synaptic plasticity, learning, and emotional responses

  139. 2018

    Micronized palmitoylethanolamide reduces joint pain and glial cell activation

    FavorávelEstudo em AnimaisDorInflamaçãoDor — Crônica+1
  140. 2018

    N-of-1 Randomized Trials of Ultra-Micronized Palmitoylethanolamide in Older Patients with Chronic Pain

    FavorávelEnsaio ClínicoDorDor — Crônica
  141. 2018

    N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice

  142. 2018

    N-Palmitoyl Ethanol Amide Pharmacological Treatment in Patients With Nonsurgical Lumbar Radiculopathy

    FavorávelEnsaio ClínicoDorDor — Crônica
  143. 2018

    N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasDoença de Parkinson
  144. 2018

    Palmitoylethanolamide Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats.

    FavorávelEstudo em AnimaisFibroseFibrose — Hepática (Cirrose)
  145. 2018

    Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial

    FavorávelEnsaio Clínico Duplo-CegoAutismo
  146. 2018

    Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial

    FavorávelEnsaio Clínico Duplo-CegoDepressão
  147. 2018

    Palmitoylethanolamide attenuates cocaine-induced behavioral sensitization and conditioned place preference in mice

    FavorávelEstudo em AnimaisDependência QuímicaDependência — Cocaína
  148. 2018

    Palmitoylethanolamide Blunts Amyloid-β42-Induced Astrocyte Activation and Improves Neuronal Survival in Primary Mouse Cortical Astrocyte-Neuron Co-Cultures

    FavorávelEstudo LaboratorialInflamaçãoDoenças NeurodegenerativasDoença de Alzheimer
  149. 2018

    Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf/J mice: Contribution of central and peripheral mechanisms

    FavorávelEstudo em AnimaisInflamaçãoEstresse OxidativoTranstornos de Comportamento+1
  150. 2018

    Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: In Vitro and In Vivo Evidence

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasDoença de Alzheimer
  151. 2018

    Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia

    FavorávelEstudo em AnimaisAVCVirodamina (O-AEA)
  152. 2018

    Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation

  153. 2018

    Prophylactic Palmitoylethanolamide Prolongs Survival and Decreases Detrimental Inflammation in Aged Mice With Bacterial Meningitis

  154. 2018

    Role of palmitoylethanolamide (PEA) in depression: Translational evidence: Special Section on "Translational and Neuroscience Studies in Affective Disorders".

    FavorávelMetanáliseDorAnsiedadeDepressãoEndocanabinoide (não especificado)+2
  155. 2018

    The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain

  156. 2018

    The Relationship of Endocannabinoidome Lipid Mediators With Pain and Psychological Stress in Women With Fibromyalgia: A Case-Control Study

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoAnsiedadeAnandamida (AEA)Endocanabinoide (não especificado)+4
  157. 2018

    Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti-inflammatory and neuroprotective effects

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasDoença de Alzheimer
  158. 2017

    Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon.

  159. 2017

    Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn’s Disease

  160. 2017

    Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis

    FavorávelMetanálise ClínicaDorDor — CrônicaDor — Aguda+1
  161. 2017

    Micronized palmitoylethanolamide/trans-polydatin treatment of endometriosis-related pain: a meta-analysis

    FavorávelMetanáliseDorDor — CrônicaEndometriose
  162. 2017

    Palmitoylethanolamide and Polydatin combination reduces inflammation and oxidative stress in vascular injury

    FavorávelEstudo em AnimaisInflamaçãoDoenças Cardiovasculares (DCV)Estresse Oxidativo+1
  163. 2017

    The Clinical Significance of Endocannabinoids in Endometriosis Pain Management

    FavorávelMetanáliseEndometrioseAnandamida (AEA)Tetraidrocanabinol (THC)+5
  164. 2017

    The efficacy of an association of palmitoylethanolamide and alpha-lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial

    FavorávelEnsaio ClínicoDorInflamaçãoDor — Crônica+2
  165. 2017

    The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations

    FavorávelMetanáliseDorInflamaçãoDor — Crônica+8
  166. 2017

    Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson's Disease

    FavorávelEnsaio ClínicoInflamaçãoDoenças NeurodegenerativasDoença de Parkinson
  167. 2017

    Use of palmitoylethanolamide in carpal tunnel syndrome: a prospective randomized study

    InconclusivoEnsaio Clínico Duplo-CegoDorInflamaçãoDor — Crônica+6
  168. 2017

    Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications

    FavorávelEnsaio ClínicoInflamaçãoGlaucoma
  169. 2016

    A Lower Olfactory Capacity Is Related to Higher Circulating Concentrations of Endocannabinoid 2-Arachidonoylglycerol and Higher Body Mass Index in Women

  170. 2016

    Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy

    FavorávelEnsaio ClínicoDoenças NeurodegenerativasEsclerose Lateral Amiotrófica (ELA)
  171. 2016

    An update on PPAR activation by cannabinoids

  172. 2016

    Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism

    FavorávelMetanáliseInflamaçãoDisfunção CognitivaTranstornos de Comportamento+1
  173. 2016

    Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDor — CrônicaAnandamida (AEA)+3
  174. 2016

    Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy

    FavorávelMetanáliseDorInflamaçãoDor — Crônica+1
  175. 2016

    Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis

  176. 2016

    Palmitoylethanolamide Reverses Paclitaxel-Induced Allodynia in Mice

    FavorávelEstudo em AnimaisDorCâncerDor — AgudaCanabinoides Sintéticos SR-x+1
  177. 2016

    Ultramicronized palmitoylethanolamide (PEA-um(®)) in the treatment of idiopathic pulmonary fibrosis

    FavorávelEstudo em AnimaisInflamaçãoFibroseFibrose — Pulmonar
  178. 2016

    Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial

    InconclusivoEnsaio Clínico Duplo-CegoDorDor — CrônicaLesões da Medula Espinhal
  179. 2015

    Cannabinoids in experimental stroke: a systematic review and meta-analysis

    FavorávelEstudo em AnimaisAVCAnandamida (AEA)Tetraidrocanabinol (THC)+6
  180. 2015

    Chronic pelvic pain, quality of life and sexual health of women treated with palmitoylethanolamide and α-lipoic acid

    FavorávelEnsaio ClínicoDorDor — CrônicaQualidade de Vida
  181. 2015

    Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa

  182. 2015

    Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study

    FavorávelEstudo em AnimaisDorInflamaçãoDor — Aguda+5
  183. 2015

    Food Liking Enhances the Plasma Response of 2-Arachidonoylglycerol and of Pancreatic Polypeptide upon Modified Sham Feeding in Humans

    FavorávelEnsaio ClínicoPancreatiteAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  184. 2015

    Palmitoyl Serine: An Endogenous Neuroprotective Endocannabinoid-Like Entity After Traumatic Brain Injury

  185. 2015

    Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors

    FavorávelEstudo em AnimaisEpilepsiaCanabinoides Sintéticos AM-x
  186. 2015

    Palmitoylethanolamide Inhibits Glutamate Release in Rat Cerebrocortical Nerve Terminals

  187. 2015

    Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats

    FavorávelEstudo em AnimaisDorInflamaçãoDiabetes+2
  188. 2015

    Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome

  189. 2014

    Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up

    FavorávelEnsaio ClínicoGlaucoma
  190. 2014

    Effectiveness of the Association N-Palmitoylethanolamine and Transpolydatin in the Treatment of Primary Dysmenorrhea

    FavorávelEnsaio ClínicoDor — AgudaGestaçãoDor — Oncológica+1
  191. 2014

    Effects of two different specific neck exercise interventions on palmitoylethanolamide and stearoylethanolamide concentrations in the interstitium of the trapezius muscle in women with chronic neck shoulder pain

  192. 2014

    Endocannabinoid Signaling in Hypothalamic-Pituitary-Adrenocortical Axis Recovery Following Stress: Effects of Indirect Agonists and Comparison of Male and Female Mice.

    FavorávelEstudo em Animais2-Araquidonoilglicerol (2-AG)Canabinoides Sintéticos SR-x+1
  193. 2014

    Harnessing the anti-inflammatory potential of palmitoylethanolamide

  194. 2014

    In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects

  195. 2014

    Is there a role for palmitoylethanolamide in the treatment of depression?

    FavorávelMetanáliseDepressão
  196. 2014

    Moderate-vigorous physical activity across body mass index in females: moderating effect of endocannabinoids and temperament

  197. 2014

    N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients

    FavorávelEnsaio Clínico Duplo-CegoInflamaçãoDoenças de PelePruridoAnandamida (AEA)+1
  198. 2014

    Palmitoylethanolamide in CNS health and disease

  199. 2013

    Effect of diet on tissue levels of palmitoylethanolamide

  200. 2013

    Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study

  201. 2013

    Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study

  202. 2013

    Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator

  203. 2013

    Measurement of palmitoylethanolamide and other N-acylethanolamines during physiological and pathological conditions

    FavorávelMetanáliseInflamaçãoSíndrome Metabólica
  204. 2013

    Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries

    FavorávelMetanáliseDorInflamaçãoLesões da Medula Espinhal+2
  205. 2013

    Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma

  206. 2013

    Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain

    FavorávelMetanáliseDorInflamaçãoDor — Crônica+1
  207. 2012

    Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans

  208. 2012

    Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice

  209. 2012

    Mast cell–glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide

  210. 2012

    Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis

    FavorávelEnsaio ClínicoDorDor — CrônicaDiabetes+5
  211. 2012

    Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain

    FavorávelEnsaio ClínicoDorInflamaçãoArtrite
  212. 2011

    Minireview: Recent Developments in the Physiology and Pathology of the Lysophosphatidylinositol-Sensitive Receptor GPR55

  213. 2011

    Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDor — CrônicaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+5
  214. 2011

    Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study

    FavorávelEnsaio ClínicoDorInflamaçãoGlaucoma+1
  215. 2011

    Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy

    FavorávelEnsaio Clínico Duplo-CegoDorDor — Neuropatia PeriféricaDor — Oncológica+1
  216. 2011

    The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease

  217. 2010

    Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations

    FavorávelEnsaio ClínicoDistúrbios MenstruaisInfecção UrináriaEndometriose
  218. 2010

    Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain.

  219. 2007

    Role of osteopathic manipulative treatment in altering pain biomarkers: a pilot study

    FavorávelEnsaio ClínicoDorAnandamida (AEA)
  220. 2005

    Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals

    FavorávelMetanáliseDorInflamaçãoDor — Aguda
  221. 2005

    The search for the palmitoylethanolamide receptor

  222. 2003

    CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?

  223. 2002

    The palmitoylethanolamide family: a new class of anti-inflammatory agents?

    FavorávelMetanáliseDorInflamaçãoDor — CrônicaAnandamida (AEA)+1
  224. 2001

    Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice.

    FavorávelEstudo em AnimaisEpilepsia

Continue por aqui

Perguntas frequentes

Quantos estudos sobre palmitoiletanolamida (pea) estão indexados no acervo?
São 224 estudos, publicados entre 2001 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 70 · Estudo em Animais: 56 · Ensaio Clínico: 48 · Ensaio Clínico Duplo-Cego: 30 · Estudo Laboratorial: 16 · Metanálise Clínica: 4. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 206 favoráveis, 10 inconclusivos e 8 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Palmitoiletanolamida (PEA) — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/canabinoide/palmitoiletanolamida-pea/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Palmitoiletanolamida (PEA) — estudos científicos sobre cannabis. https://cannabisindica.com.br/canabinoide/palmitoiletanolamida-pea/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.